Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma

Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening with microbubbles is an emerging technology that enables drug delivery for central nervous system diseases. To date, most clinical trials assessing BBB opening in adults were designed to deliver US with a frequency of one treatment over several weeks. Little is known about the feasibility of shorter intervals of US delivery or whether this can be achieved in a pediatric population using a mobile device. Here, FUS and panobinostat were shown to have additive therapeutic effects in a syngeneic orthotopic model of diffuse midline glioma (DMG). We then conducted a single-arm first-in-pediatric trial to investigate the safety and feasibility of delivering neuronavigation-guided FUS treatment in combination with oral panobinostat in children with relapsed DMGs. We included an intrapatient escalation of FUS delivery to assess the feasibility of opening multiple sites in the brain. We demonstrated successful BBB opening using neuronavigation-guided FUS as frequently as every 2 days. Magnetic resonance imaging with contrast was used to identify the region of BBB opening. Three patients were accrued; 22 FUS procedures were delivered for 1 NOTS (number of tumor sites) treated, and four FUS procedures were delivered for 2 NOTS. All three patients received 1 NOTS, without serious adverse events, and two of the patients received 2 NOTS, all without sedation. For 2 NOTS, prolonged BBB opening and one grade 5 event, unlikely related to FUS, were observed. This study demonstrates feasibility of FUS for BBB opening and drug delivery without sedation in pediatric patients.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2025-11-12
DOI
https://doi.org/10.1126/scitranslmed.adq6645
Citations
5
Primary Topic
Ultrasound and Hyperthermia Applications
Type
article
Field-Weighted Citation Impact
3.37

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma

Elisa E. Konofagou, Neil A. Feldstein, Zachary Englander, Angela Lignelli et al.
5 citations
Science Translational Medicine
Ultrasound and Hyperthermia Applications
3.37
article

Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma

Elisa E. Konofagou, Neil A. Feldstein, Zachary Englander, Angela Lignelli, Sua Bae, Alexis Maddocks, Masih Tazhibi, Danae Kokossis, Nicholas McQuillan, Xander Berg, Robyn D. Gartrell, Cheng–Chia Wu, Omid Yousefian, Luca Szalontay, Stergios Zacharoulis, Jovana Pavisic, Peter Canoll, Nina Yoh, Zhezhen Jin, Matthew Gallitto, Hong-Jian Wei, Antonios N. Pouliopoulos, Robin Ji, Andrea Webster Carrion, Chankrit Sethi, James H. Garvin, Jennifer Lipina, Keyu Liu, Jessica Fino, Genesis De Los Santos, Halina Shatravka
article en
5 citations

Abstract

Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening with microbubbles is an emerging technology that enables drug delivery for central nervous system diseases. To date, most clinical trials assessing BBB opening in adults were designed to deliver US with a frequency of one treatment over several weeks. Little is known about the feasibility of shorter intervals of US delivery or whether this can be achieved in a pediatric population using a mobile device. Here, FUS and panobinostat were shown to have additive therapeutic effects in a syngeneic orthotopic model of diffuse midline glioma (DMG). We then conducted a single-arm first-in-pediatric trial to investigate the safety and feasibility of delivering neuronavigation-guided FUS treatment in combination with oral panobinostat in children with relapsed DMGs. We included an intrapatient escalation of FUS delivery to assess the feasibility of opening multiple sites in the brain. We demonstrated successful BBB opening using neuronavigation-guided FUS as frequently as every 2 days. Magnetic resonance imaging with contrast was used to identify the region of BBB opening. Three patients were accrued; 22 FUS procedures were delivered for 1 NOTS (number of tumor sites) treated, and four FUS procedures were delivered for 2 NOTS. All three patients received 1 NOTS, without serious adverse events, and two of the patients received 2 NOTS, all without sedation. For 2 NOTS, prolonged BBB opening and one grade 5 event, unlikely related to FUS, were observed. This study demonstrates feasibility of FUS for BBB opening and drug delivery without sedation in pediatric patients.

Science Translational MedicineVol. 17(824)
Children's Hospital of Philadelphia (US), Johns Hopkins University (US), Washington University in St. Louis (US), Columbia University Irving Medical Center (US), Johns Hopkins Medicine (US), Neurological Surgery (US), Columbia University (US)
Musella Foundation For Brain Tumor Research and Information, Rally Foundation, Focused Ultrasound Foundation, Memorial Sloan-Kettering Cancer Center, George Washington University, Virginia Polytechnic Institute and State University, Strong, Swim Across America, Children's National Hospital, King's College London, Sogang University, National Institutes of Health, Hyundai Hope On Wheels
Openalex Percentile: Top 7%
Ultrasound and Hyperthermia Applications
3.37
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.